Whalesbook
Regulator Ki Warning, Campaign Band!
Asal mein, India ke regulator ne Eli Lilly ko bola hai ki unka yeh 'We Know Now' wala campaign, jisme newspaper ads, social media aur celebrity endorsements sab the, woh prescription medicines ko indirectly promote karne wale laws ko tod raha hai. Isliye, company ne 'regulatory caution' dikhate hue campaign ko pause kar diya hai. Eli Lilly ko India ke strict promotional rules clear nahi lag rahe, jo US se kaafi alag hain. Unhe lagta hai ki doctor-led awareness campaigns bhi restrict ho sakte hain, jo public health ke liye achha nahi hai.
India Ka Obesity Market Aur Competition:
Dekho, India mein obesity aur diabetes ki medicines ka market bahut tezi se badh raha hai. Estimates hain ki yeh ₹80 billion (around $839 million) tak pahunch sakta hai 2030 tak. Eli Lilly ka GLP-1 treatment, Mounjaro, jo March 2025 mein launch hua tha, woh already India ka top-selling drug ban gaya hai. Lekin yahan competition bhi tagda hai, khaas kar Novo Nordisk ke Ozempic aur Wegovy se. April 2026 mein Novo Nordisk ne price cuts ke baad sales mein 40% ka jump dekha.
Generic Drugs Ka Pressure Aur Rules Ki Jungle:
Yeh bhi bata du ki March 2026 tak, 13 manufacturers ke generic semaglutide products market mein aa gaye hain, jis se Eli Lilly ka market share thoda kam hua hai. Is sab ke beech, India ke laws prescription drugs ki public advertising bilkul mana karte hain, chahe woh indirect hi kyun na ho. Eli Lilly ka campaign, bhale hi Mounjaro ka naam nahi le raha tha, par regulator ko lagta hai ki yeh product ko visible bana raha tha. India mein physician-led consultations par focus hai, jo bade consumer campaigns ke liye mushkil hai. Aur market price-sensitive hai, jaisa Novo Nordisk ke price cuts se pata chalta hai.
Aage Kya? Investors Kya Soch Rahe Hain?
Global obesity drug market $150 billion tak pahunchne ka chance hai 2030 tak. Eli Lilly ke liye India mein regulations ko follow karte hue apni marketing strategy adjust karna aur competition mein banaye rakhna bahut important hoga. Unka P/E ratio lagbhag 34.1x hai, jo future earnings par investor confidence dikhata hai.